Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
Sue & Bill Gross School of Nursing, University of California Irvine, Irvine, CA.
Medicine (Baltimore). 2024 Jan 19;103(3):e36804. doi: 10.1097/MD.0000000000036804.
Omega-3 supplements are endorsed for heart failure (HF) patients to reduce hospitalizations and mortality, offering anti-inflammatory and cardioprotective benefits.
A comprehensive search was conducted in various databases until November 2022. Eligible studies included clinical trials on patients with HF. Data extraction covered study details, omega-3 specifics, outcomes, and limitations. The JADAD scale was used to assess the risk of bias in randomized controlled trials.
The review process involved 572 records from database searches, resulting in 19 studies after eliminating duplicates and screening. These studies assessed the impact of omega-3 on various clinical outcomes, such as mortality, hospitalization, cardiac function, and quality of life. Studied duration varied from weeks to years. Omega-3 supplementation demonstrated potential benefits such as improved heart function, reduced inflammation, and decreased risk of cardiovascular events.
Omega-3 supplementation could benefit heart disease treatment, potentially reducing therapy duration and improving outcomes. Starting omega-3 supplementation for HF patients seems favorable.
欧米伽-3 补充剂被推荐用于心力衰竭（HF）患者，以减少住院和死亡率，提供抗炎和心脏保护作用。
在 2022 年 11 月之前，我们在各种数据库中进行了全面搜索。合格的研究包括 HF 患者的临床试验。数据提取涵盖了研究细节、欧米伽-3 的具体情况、结果和局限性。JADAD 量表用于评估随机对照试验的偏倚风险。
综述过程涉及数据库搜索的 572 条记录，经过重复和筛选后，最终纳入 19 项研究。这些研究评估了欧米伽-3 对各种临床结局的影响，如死亡率、住院率、心功能和生活质量。研究持续时间从数周到数年不等。欧米伽-3 补充剂显示出潜在的益处，如改善心脏功能、减轻炎症和降低心血管事件风险。
欧米伽-3 补充剂可能有益于心脏病治疗，有可能减少治疗持续时间并改善结局。对 HF 患者开始欧米伽-3 补充似乎是有利的。
